Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Absci Corporation filings document a Nasdaq-listed clinical-stage biotechnology issuer developing generative AI-designed biologic therapeutics. Its 8-K reports furnish quarterly and annual financial results, business presentations, and internal pipeline updates for programs such as ABS-201 and the broader prolactin and PRLR portfolio.
Proxy and material-event filings cover board and shareholder matters, executive compensation and equity-plan governance, director and officer indemnification agreements, common stock registered on the Nasdaq Global Select Market, and amendments to material agreements related to prior corporate transactions.
Absci Corp director Karen K. McGinnis received new equity awards. She was granted 10,100 Restricted Stock Units, each representing one share of common stock, increasing her direct common stock holdings to 48,420 shares. She also received stock options for 39,800 shares at an exercise price of $7.34 per share.
Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholders’ meeting, conditioned on her continuous service to the company.
Absci Corp director Mary T. Szela reported equity awards consisting of restricted stock units and stock options. She received 10,100 shares of Common Stock in the form of restricted stock units under the Absci Corporation 2021 Stock Option and Incentive Plan, with each unit representing one share.
She was also granted options over 39,800 shares of Common Stock at an exercise price of $7.3400 per share, expiring on June 3, 2036. Both the restricted stock units and the options vest in full on the earlier of the first anniversary of the June 4, 2026 grant date or the company’s next annual stockholder meeting, subject to her continuous service. Following these awards, her reported direct holdings are 10,100 shares of Common Stock and options over 39,800 shares.
Absci Corp director Menelas N. Pangalos received new equity awards. He was granted 10,100 Restricted Stock Units, each representing one share of common stock, and stock options for 39,800 shares at an exercise price of $7.34. Both awards vest in full on the earlier of the first anniversary of grant or Absci’s next annual stockholder meeting, subject to his continued service. After the RSU grant, he holds 242,408 common shares directly, plus the newly granted options.
Absci Corp director Frans Van Houten received new equity compensation consisting of restricted stock units and stock options. He was granted 10,100 RSUs, each representing one share of common stock, under the Absci Corporation 2021 Stock Option and Incentive Plan.
The RSUs vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, contingent on continued service. He also received stock options for 39,800 shares of common stock at an exercise price of $7.34 per share, vesting on the same schedule. Following the RSU grant, his direct common stock holdings total 73,420 shares.
Absci Corp director Daniel A. Rabinovitsj received new equity awards in the form of restricted stock units and stock options. He was granted 10,100 RSUs, each representing the right to receive one share of common stock. After this grant, he directly holds 33,420 common shares.
He was also granted options on 39,800 shares of common stock at an exercise price of $7.34 per share, expiring in 2036. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, as long as he continues serving the company.
Absci Corp director Joseph Sirosh received new equity awards. He was granted 10,100 Restricted Stock Units, each representing one share of common stock, and a stock option for 39,800 shares at an exercise price of $7.34 per share.
The RSUs and options each vest in full on the earlier of the first anniversary of the grant date or Absci’s next annual stockholder meeting, as long as he continues serving the company. After the RSU grant, Sirosh directly holds 33,420 common shares, and he now also holds the new option award.
Absci Corporation reported the results of its Annual Meeting of Stockholders held on June 4, 2026. As of the April 7, 2026 record date, 155,447,428 common shares were outstanding and entitled to vote.
Stockholders elected Class II directors Prof Sir Menelas Pangalos, Ph.D. (74,118,258 votes for, 9,332,380 withheld, 29,904,399 broker non-votes) and Daniel Rabinovitsj (69,590,534 votes for, 13,860,104 withheld, 29,904,399 broker non-votes) to serve until the 2029 annual meeting. They also ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 111,058,992 votes for, 2,198,390 against, and 97,655 abstentions. No other matters were submitted to stockholders.
Absci Corp CFO/CBO Zachariah Jonasson reported a Form 4 transaction where 8,319 shares of common stock were withheld by the company at $6.75 per share to cover tax obligations from vesting restricted stock units.
The filing explains this was a tax-withholding disposition, not a discretionary market trade. After this withholding, Jonasson directly owns 491,464 shares of Absci common stock, showing he retains a substantial equity position in the company.
Absci Corp director Menelas N. Pangalos bought additional company stock in the open market. He purchased 37,453 shares of Absci Corp Common Stock at a price of $5.36 per share. After this transaction, he directly owns 232,308 shares, reflecting a larger personal stake aligned with the company’s equity.
Absci Corporation reported a net loss of $29.6 million for the three months ended March 31, 2026, as it continues to invest in its AI‑driven antibody pipeline. Partner program revenue was $0.2 million, down sharply from $1.2 million a year earlier due to milestone timing and program mix.
Research and development expenses rose to $19.3 million, reflecting higher external preclinical and clinical spending on lead candidate ABS-201 and broader platform work. Selling, general and administrative costs edged down to $9.1 million, while depreciation and amortization fell to $2.7 million as certain lab equipment was retired.
Cash, cash equivalents and marketable securities totaled $125.7 million as of March 31, 2026, against an accumulated deficit of $654.4 million. The company raised $8.0 million in net proceeds via its at‑the‑market equity program and continues to expect significant ongoing spending on clinical development and its Integrated Drug Creation platform.